| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5770619 | VALEANT LUXEMBOURG | Method of activating photosensitive agents |
Jan, 2015
(9 years ago) | |
| US5707608 | VALEANT LUXEMBOURG | Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer |
Aug, 2015
(8 years ago) | |
| US5798349 | VALEANT LUXEMBOURG | Use of green porphyrins to treat neovasculature in the eye |
Aug, 2015
(8 years ago) | |
| US5756541 | VALEANT LUXEMBOURG | Vision through photodynamic therapy of the eye |
Mar, 2016
(8 years ago) | |
Visudyne is owned by Valeant Luxembourg.
Visudyne contains Verteporfin.
Visudyne has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Visudyne are:
- US5770619
- US5707608
- US5798349
- US5756541
Visudyne was authorised for market use on 12 April, 2000.
Visudyne is available in injectable;injection dosage forms.
Visudyne can be used as use of the drug product in photodynamic therapeutic protocols for the treatment of age-related macular degeneration and related conditions involving unwanted neovasculature in the eye.
The generics of Visudyne are possible to be released after 11 March, 2016.
Drugs and Companies using VERTEPORFIN ingredient
Market Authorisation Date: 12 April, 2000
Treatment: Use of the drug product in photodynamic therapeutic protocols for the treatment of age-related macular degeneration and related conditions involving unwanted neovasculature in the eye
Dosage: INJECTABLE;INJECTION
VISUDYNE family patents
